Abstract:662 Background: For patients with localized pancreatic adenocarcinoma, resection and systemic therapy remain the mainstays of curative-intent treatment. Neoadjuvant chemotherapy has been frequently employed with the goals of addressing systemic disease early and improving patient selection for surgery. Those who do not respond to neoadjuvant therapy present a challenge with a lack of randomized data to aid in decision making. Here we sought to define the characteristics and outcomes of those patients to guide clinical practice. Methods: This was a single-institution retrospective cohort study using a prospectively maintained database of those diagnosed with pancreatic adenocarcinoma. Patients included in the study were those who received neoadjuvant chemotherapy. Non-responders were defined as those with both no radiographic and no biochemical response at the first re-assessment after initiation of therapy. Results: A total of 176 patients were identified who were treated with neoadjuvant chemotherapy with curative intent. Of those, 42 (23.8%) patients had no evidence of either radiographic or biochemical response. Of those patients, 14 were upfront resectable (33.3%) and 20 were borderline resectable (47.6%). An additional 8 (19%) were locally advanced. Most patients received FOLFIRINOX as a first line chemotherapy agent (n = 25, 59.5%). A total of 12 (28.6%) patients underwent neoadjuvant radiation therapy. A total of 19 (45.2%) proceeded to surgery and two of those were found to be unresectable at exploration, resulting in 17 (40.5%) who ultimately received curative-intent resection. Exactly half (n = 21) of the patients had their chemotherapy switched (CS). Of those who had CS, 11 (52.4%) had evidence of local tumor progression on their initial restaging scan compared to just 3 (14.3%) of those who did not (p = 0.02). Additionally, patients who had CS had higher incidence of vascular involvement on their initial scan (90.5% vs 52.3%, p = 0.051). A total of 6 (28.6%) who underwent CS had subsequent biochemical response compared 4 (19.0%) of those who did not. Ultimately, 6 (28.6%) of those who had CS ultimately proceeded to surgery compared to 13 (61.9%) of those who did not (p = 0.062). Interestingly, there was no significant difference in median overall survival between those who had CS (18.6 months) and those who did not (19.9 months, p = 0.525). Conclusions: Non-responders to frontline neoadjuvant systemic therapy present a clinical challenge and have poor rates of curative-intent resection. Chemotherapy switch was employed mostly in cases with worse prognostic factors and thus infrequently lead to resection. Despite this, patients who underwent CS had similar overall survival to those who did not. These data suggest there may be a role for chemotherapy switch in those who do not respond to front line chemotherapy.

Neoadjuvant chemo(radio)therapy in upfront resectable pancreatic cancer – can we stratify patients better in the future?

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

Neoadjuvant chemotherapy vs upfront resection: A challenging choice in resectable pancreatic ductal adenocarcinoma.

Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer

Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature

Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer

Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database

Neoadjuvant Therapy for Resectable Pancreatic Cancer: a Narrative Review

Non-responders to neoadjuvant chemotherapy in pancreatic adenocarcinoma: Characteristics and outcomes.

Selecting Chemotherapy for Pancreatic Cancer: Far Away or So Close?

Neoadjuvant treatment for pancreatic cancer: Controversies and advances

Evaluation of neoadjuvant therapy for pancreatic cancer: is it the best choice?

Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling

The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain

Long-term Survival Benefit of Upfront Chemotherapy in Patients with Newly Diagnosed Borderline Resectable Pancreatic Cancer.

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges

Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials

Personalized treatment in localized pancreatic cancer

Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how

Effect of Neoadjuvant Radiotherapy on Survival of Non-Metastatic Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis